Celgene opens new headquarters in UK
pharmafile | November 21, 2011 | News story | Research and Development, Sales and Marketing | Celgene
Celgene has opened new UK headquarters in London as its haematology-based business expands.
The firm says it has decided to relocate its UK headquarters from Windsor in Berkshire to Stockley Park, which is situated near Heathrow airport and is also the home of GlaxoSmithKline’s UK operations.
Celgene said the change would accommodate its growing numbers of UK staff and its regulatory and drug safety teams, who are part of a global network.
The company is thriving thanks to the success of multiple myeloma treatment Revlimid and myelodysplastic syndromes drug Vidaza (azacitidine), as well as its recent $2.9 billion acquisition of Abraxis BioScience, and its lead product Abraxane (nab-paclitaxel) for metastatic breast cancer.
The new London site was officially opened by David Willetts, minister for Universities and Science, who said: “The government is committed to making Britain the best place in the world to do business.
“Celgene’s expansion is a vote of confidence in the UK pharmaceutical industry and shows the ability of our life sciences sector to drive growth and create jobs.”
Sam Pearce, general manager, UK and Ireland said: “The launch of our new UK headquarters today is another step in Celgene’s continued expansion in the UK.
“We are a company that is founded on innovation and at the core of our business is the passion to develop life-changing clinical advances in disease areas which have been overlooked or where the biggest unmet need exists.
“We hope that our continued focus on scientific excellence combined with our long term investment in research will make a significant difference to patients’ lives.”
Ben Adams
Related Content
NICE recommends Celgene’s REVLIMID for multiple myeloma
NICE has issued a Final Appraisal Document (FAD) recommending Celgene’s REVLIMID (lenalidomide) as maintenance treatment …
NICE opts to reject Celgene’s Revlimid for newly diagnosed multiple myeloma after an autologous stem cell transplant
It has emerged that NICE has opted to reject Celgene’s Revlimid (lenalidomide) for the maintenance …
NICE recommends Celgene’s Revlimid combo for follicular lymphoma
NICE has chosen to recommend Celgene’s Revlimid (lenalidomide) for use on the NHS, it has …
